313 related articles for article (PubMed ID: 17179993)
1. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Temmink OH; Prins HJ; van Gelderop E; Peters GJ
Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
[TBL] [Abstract][Full Text] [Related]
2. Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines.
Temmink OH; de Bruin M; Turksma AW; Cricca S; Laan AC; Peters GJ
Int J Biochem Cell Biol; 2007; 39(3):565-75. PubMed ID: 17098463
[TBL] [Abstract][Full Text] [Related]
3. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity.
de Bruin M; van Capel T; Van der Born K; Kruyt FA; Fukushima M; Hoekman K; Pinedo HM; Peters GJ
Br J Cancer; 2003 Mar; 88(6):957-64. PubMed ID: 12644837
[TBL] [Abstract][Full Text] [Related]
4. The effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor on the expression of thymidine phosphorylase.
De Bruin M; Van Capel T; Smid K; Fukushima M; Hoekman K; Pinedo HM; Peters GJ
Eur J Pharmacol; 2004 May; 491(2-3):93-9. PubMed ID: 15140625
[TBL] [Abstract][Full Text] [Related]
5. Radiosensitization by thymidine phosphorylase inhibitor in thymidine phosphorylase negative and overexpressing bladder cancer cell lines.
El-Naggar M; Ebbing E; Bijnsdorp I; van den Berg J; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):413-21. PubMed ID: 24940699
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
Morita T; Matsuzaki A; Tokue A
Int J Cancer; 2001 May; 92(3):451-6. PubMed ID: 11291085
[TBL] [Abstract][Full Text] [Related]
7. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
Emura T; Suzuki N; Fujioka A; Ohshimo H; Fukushima M
Int J Oncol; 2005 Aug; 27(2):449-55. PubMed ID: 16010427
[TBL] [Abstract][Full Text] [Related]
9. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K
Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.
Temmink OH; Emura T; de Bruin M; Fukushima M; Peters GJ
Cancer Sci; 2007 Jun; 98(6):779-89. PubMed ID: 17441963
[TBL] [Abstract][Full Text] [Related]
11. IFN gamma-induced up-regulation of PD-ECGF/TP enhances the cytotoxicity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in bladder cancer cells.
Li G; Kawakami S; Kageyama Y; Yan C; Saito K; Kihara K
Anticancer Res; 2002; 22(5):2607-12. PubMed ID: 12529971
[TBL] [Abstract][Full Text] [Related]
12. Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells.
Temmink OH; de Bruin M; Comijn EM; Fukushima M; Peters GJ
Anticancer Drugs; 2005 Mar; 16(3):285-92. PubMed ID: 15711180
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of the anti-tumor effect of 5'-deoxy-5-fluorouridine by transfection of thymidine phosphorylase gene into human colon cancer cells.
Kanyama H; Tomita N; Yamano T; Miyoshi Y; Ohue M; Fujiwara Y; Sekimoto M; Sakita I; Tamaki Y; Monden M
Jpn J Cancer Res; 1999 Apr; 90(4):454-9. PubMed ID: 10363585
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine.
Temmink OH; Hoebe EK; Fukushima M; Peters GJ
Eur J Cancer; 2007 Jan; 43(1):175-83. PubMed ID: 17049227
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy.
Chung YL; Troy H; Judson IR; Leek R; Leach MO; Stubbs M; Harris AL; Griffiths JR
Clin Cancer Res; 2004 Jun; 10(11):3863-70. PubMed ID: 15173095
[TBL] [Abstract][Full Text] [Related]
16. Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity.
Guichard SM; Macpherson JS; Mayer I; Reid E; Muir M; Dodds M; Alexander S; Jodrell DI
Eur J Cancer; 2008 Jan; 44(2):310-7. PubMed ID: 18077151
[TBL] [Abstract][Full Text] [Related]
17. Review on TAS-102 development and its use for metastatic colorectal cancer.
Mota JM; Fonseca LG; Braghiroli MI; Hoff PM
Crit Rev Oncol Hematol; 2016 Aug; 104():91-7. PubMed ID: 27296058
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
Temmink OH; Hoebe EK; van der Born K; Ackland SP; Fukushima M; Peters GJ
Br J Cancer; 2007 Jan; 96(2):231-40. PubMed ID: 17242697
[TBL] [Abstract][Full Text] [Related]
20. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Emura T; Murakami Y; Nakagawa F; Fukushima M; Kitazato K
Int J Mol Med; 2004 Apr; 13(4):545-9. PubMed ID: 15010854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
